Boehringer Ingelheim has been operating in Greece since 1966. It has already completed 40 years since the opening of the industrial production unit in Koropi, Attica, which set new data in the industrial sector of the country. Today it continues to maintain its own industrial unit for the production of innovative medicines in Greece, catering not only to the Greek market but also to the markets of more than 65 countries. about 1% of Greece's total exports.
The company also invests in Greece by conducting clinical trials for its innovative drugs.
Boehringer Ingelheim Ellas's strategy is to attract the strongest minds and promote diversity in the workplace. It encourages all employees to develop their talents and to know that their personal characteristics as well as their knowledge and experiences are a capital for the company.